Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

Study Purpose

The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	Unknown
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational [Patient Registry]
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Confirmed MM diagnosis.

- Transplant eligible patients in a first remission.

- Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed) - Availability of deidentified patient's demographic and clinical follow up data.

- Receiving standard of care treatment.

- Able to provide informed consent.

Exclusion Criteria:

- Failure to meet inclusion criteria

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05530096
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Sir Mortimer B. Davis - Jewish General Hospital
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Rayan Kaedbey
Principal Investigator Affiliation	Sir Mortimer B. Davis - Jewish General Hospital
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Not yet recruiting
Countries
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Multiple Myeloma

Arms & Interventions

Arms

: MRD level group

Participants will be defined as diagnosed with multiple myeloma

Interventions

Diagnostic Test: - Standard of care

Participants will not receive any intervention in this study. Participants will receive standard of care therapy

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Rayan Kaedbey, MD FRCPC

rayan.kaedbey.med@ssss.gouv.qc.ca

514-340-8222

For additional contact information, you can also visit the trial on clinicaltrials.gov.

Clinical Trial Finder